Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21558089 | 0.80 | DPP4 (0.40) | DPP4ALDH1A1 | |
| SCHEMBL21558067 | 0.79 | DPP4 (0.34) | DPP4 | |
| SCHEMBL23411444 | 0.73 | DPP4 (0.31) | DPP4 | |
| SCHEMBL20217598 | 0.71 | DPP4 (0.34) | DPP4 | |
| SCHEMBL23086688 | 0.71 | DPP4 (0.36) | DPP4ALDH1A1GAA | |
| SCHEMBL17146470 | 0.71 | — | — | |
| SCHEMBL3530585 | 0.71 | MEN1 (0.34) | TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL14986221 | 0.70 | DPP4 (0.38) | DPP4TSHR | |
| SCHEMBL6201919 | 0.70 | ALDH1A1 (0.36) | DPP4ALDH1A1GAA | |
| SCHEMBL4818284 | 0.69 | MEN1 (0.36) | TSHRMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319683-B2 | Azabenzimidazole compounds and pharmaceutical | NIPPON SHINYAKU CO., LTD. (JP) | 2025-06-03 | — | — | US | disclosed |
| EP-3792260-B1 | AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL | NIPPON SHINYAKU CO LTD (JP) | 2024-09-11 | — | — | EP | disclosed |
| US-20210371412-A1 | AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2021-12-02 | — | — | US | disclosed |
| EP-3792260-A1 | AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL | Nippon Shinyaku Co., Ltd. (JP) | 2021-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371412-A1 | AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL | PAM, CHRM3, AZI2 | DPP4 419/4885TSHR 3490/4885SMN1; SMN2 1008/4885 |
| US-12319683-B2 | Azabenzimidazole compounds and pharmaceutical | PAM, CHRM3, AZI2 | DPP4 419/4885TSHR 3490/4885SMN1; SMN2 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.